FDA CANCELS PART 11 MEETING; PRESENTATIONS TO BECOME COMMENTS

Drug Industry Daily
KEYWORDS FDA / Part 11
A A

The FDA’s decision to cancel its June 11 public meeting to address possible Part 11 rule revisions has exacerbated an already confused situation in which industry has been unable to get a clear fix on the agency’s direction regarding electronic signatures and electronic recordkeeping.

To View This Article:

Login

Subscribe To Drug Industry Daily